InfliximabDrug ineffective and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2025年 / 2051卷 / 1期

关键词：

D O I：

10.1007/s40278-025-79667-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：147 / 147

相关论文

共 50 条

[31] DexamethasoneAspergillosis secondary to off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 177 - 177
[32] TocilizumabAnaphylaxis following off-label use: case report
Reactions Weekly, 2021, 1865 (1) : 397 - 397
[33] MirtazapineTachyphylaxis following off-label use: case report
Reactions Weekly, 2018, 1703 (1) : 182 - 182
[34] RituximabPancytopenia following off-label use: case report
Reactions Weekly, 2020, 1807 (1) : 176 - 176
[35] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[36] OsimertinibLack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1949 (1) : 349 - 349
[37] Multiple drugsLymphocytopenia and off-label use: case report
Reactions Weekly, 2020, 1831 (1) : 207 - 207
[38] Omeprazole/teduglutideHypomagnesaemia and off-label use: case report
Reactions Weekly, 2021, 1837 (1) : 546 - 546
[39] RituximabLack of efficacy in off-label use: case report
Reactions Weekly, 2023, 1946 (1) : 492 - 492
[40] IvabradinePhosphenes during off-label use: case report
Reactions Weekly, 2018, 1688 (1) : 137 - 137

← 1 2 3 4 5 →